不同化疗方案治疗多发性骨髓瘤患者的临床疗效

Clinical efficacy of different chemotherapy regimens in the treatment of patients with multiple myeloma

目的目的比较硼替佐米+环磷酰胺+地塞米松(BCD)和硼替佐米+来那度胺+地塞米松(VRD)方案对多发性骨髓瘤(MM)患者的治疗效果。方法方法根据化疗方案的不同将105例MM患者分为BCD组(n=55)和VRD组(n=50)。比较两组患者的临床疗效、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]、不良反应发生情况及预后情况。结果结果VRD组患者的客观缓解率高于BCD组,不良反应总发生率低于BCD组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者EORTC QLQ-C30各维度评分均高于本组治疗前,VRD组患者EORTC QLQ-C30各维度评分均高于BCD组,差异均有统计学意义(P﹤0.05)。随访6个月,两组患者的生存率及复发率比较,差异均无统计学意义(P﹥0.05)。结论结论与BCD方案相比,VRD方案治疗MM患者可提高临床疗效和生活质量,降低不良反应发生率。

Objective To compare the efficacy of bortezomib+cyclophosphamide+dexamethasone(BCD)and bort-ezomib+lenalidomide+dexamethasone(VRD)regimens in the treatment of patients with multiple myeloma(MM).Method According to different chemotherapy regimens,105 MM patients were divided into BCD group(n=55)and VRD group(n=50).The clinical efficacy,quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)],incidence of adverse reactions and prognosis were compared between the two groups.Result The objective response rate of VRD group was higher than that of BCD group,and the total incidence of adverse reactions was lower than that of BCD group,and the differences were statistically significant(P<0.05).After treatment,the scores of each dimension of EORTC QLQ-C30 in both groups were higher than those be-fore treatment,and the scores of each dimension of EORTC QLQ-C30 in VRD group were higher than those in BCD group,and the differences were statistically significant(P<0.05).After 6 months of follow-up,there were no significant differences in survival rate and recurrence rate between the two groups(P>0.05).Conclusion Compared with BCD regi-men,VRD regimen can improve clinical efficacy and quality of life in MM patients,and reduce the incidence of adverse reactions.